伴同性診斷市場規模、佔有率和成長分析：按產品/服務、技術、適應症和地區 - 產業預測，2024-2031 年

2022年全球伴同性診斷市場規模將為66.2億美元，從2023年的73.7億美元成長到2031年的174.8億美元，並且預計在預測期內（2024-2031年）將以複合年成長率成長。年為11.4%。

伴同性診斷對於安全有效地使用某些生物製藥和藥物至關重要，特別是在癌症的診斷和治療中。這些測試對於透過識別特定的生物標記為個別患者量身定做治療策略至關重要。例如，Foundation Medicine 的 FOUNDATIONONE CDx 是一種出色的伴同性診斷，可對 300 多個癌症相關基因進行全面分析。這種詳細的基因分析提供了重要的見解，將有助於指導針對各種固體癌的標靶治療和個人化癌症治療的選擇。伴同性診斷使醫療保健專業人員能夠做出明智的治療方法，從而顯著提高根據患者個體需求量身定做的癌症治療的有效性和安全性。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價格分析
• 價值鏈分析
• 供應鏈分析
• 貿易分析
• 市場生態系統
• Start-Ups分析
• 專利分析
• 客戶和購買標準分析
• 監管環境
• 創新矩陣
• 重點投資分析
• 關鍵成功因素
• 市場魅力指數
• 競爭程度

伴同性診斷市場：依產品/服務分類

• 市場概況
• 測定、套件和試劑
• 設備和系統
• 軟體服務

伴同性診斷市場：依技術分類

• 市場概況
• 聚合酵素鏈鎖反應
• 原位雜合技術
• 次世代定序
• 免疫組織化學
• 其他技術

伴同性診斷市場：依適應症分類

• 市場概況
• 癌症
  • 肺癌
  • 乳癌
  • 血癌
  • 大腸直腸癌
  • 其他癌症
• 神經系統疾病
• 心血管疾病
• 感染疾病
• 其他適應症

伴同性診斷市場：依樣本類型

• 市場概況
• 組織樣本
• 血液樣本
• 其他樣品類型

伴同性診斷市場：依最終用戶分類

• 市場概況
• 製藥和生物技術公司
• 參考實驗室
• 醫療保健/製藥
• 其他最終用戶

伴同性診斷市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• IDEXX Laboratories, Inc.（US）
• Zoetis Inc.（US）
• Heska Corporation（US）
• Thermo Fisher Scientific, Inc.（US）
• Virbac SA（France）
• IDVet（France）
• NEOGEN Corporation（US）
• bioMerieux SA（France）
• Randox Laboratories Ltd.（UK）
• AniCell Biotech（US）
• Bionote Inc.（South Korea）
• Bio-Rad Laboratories, Inc.（US）
• Antech Diagnostics（US）
• Eurofins Scientific SE（Luxembourg）
• Animalytix LLC（US）
• Advanced Animal Diagnostics（US）
• Roche Diagnostics（Switzerland）
• Agilent Technologies, Inc.（US）
• Myriad Genetics, Inc.（US）
• Illumina, Inc.（US）
• Qiagen NV（Netherlands）

Global Companion Diagnostic Market size was valued at USD 6.62 billion in 2022 and is poised to grow from USD 7.37 billion in 2023 to USD 17.48 billion by 2031, growing at a CAGR of 11.4% in the forecast period (2024-2031).

Companion diagnostics are essential for the safe and effective use of specific biological products or medications, especially in cancer diagnosis and treatment. These tests are pivotal in customizing therapeutic strategies for individual patients by identifying particular biomarkers. For instance, Foundation Medicine's FOUNDATIONONE CDx is a notable companion diagnostic that offers a thorough analysis of over 300 cancer-related genes. This detailed genetic analysis provides critical insights that help in selecting targeted and personalized cancer treatments for a wide range of solid tumors. By enabling healthcare professionals to make well-informed decisions about treatment options, companion diagnostics significantly improve both the efficacy and safety of cancer therapies tailored to individual patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Diagnostic Market Segmental Analysis

The Companion Diagnostic Market is segmented based on product and services, Technology, indication and region. Based on product and services, the market is segmented into assay kits and reagents, and software and services. Based on industry, the market is segmented into polymerase chain reaction, immunohistochemistry, in situ hybridization, and next-generation sequencing, among others. Based on indication, the market is segmented into oncology, neurology, and others. Based on region, the market is segmented into North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Drivers of the Global Companion Diagnostic Market

Recent years have seen a significant rise in cancer cases, leading to increased demand for effective Companion Diagnostic (CDx) assays. This growing prevalence highlights the importance of genomic testing, which provides a detailed understanding of tumors' genetic profiles. Genomic testing helps characterize the genetic makeup of tumors and offers precise guidance to healthcare professionals on appropriate treatment strategies. Consequently, the rise in cancer cases is driving up sales of CDx products. These diagnostics are crucial for personalizing treatment approaches, ensuring that patients receive targeted therapies based on their tumors' specific genetic features, and ultimately improving the effectiveness of cancer care.

Restraints in the Global Companion Diagnostic Market

Despite the increasing acceptance of companion diagnostic tests, a significant challenge remains due to the lack of a standardized method for setting reimbursement rates. Currently, these rates are determined on a case-by-case basis, leading to inconsistencies in the reimbursement process. For instance, our analysis reveals that in Germany, there is a notable variance in reimbursement structures between inpatient and outpatient care settings. In the inpatient system, diagnostics are generally covered under diagnosis-related groups, which provides a standardized approach within this context.

Market Trends of the Global Companion Diagnostic Market

Clinicians use Next-Generation Sequencing (NGS) to analyze a broad array of genes related to cancer development, utilizing surgically excised tumor samples from patients. NGS is distinguished by its ability to produce extensive genetic data quickly, making it a crucial tool in oncology. Ongoing technological advancements continue to improve the accuracy and effectiveness of this sequencing technique. According to a publication by the Centers for Disease Control and Prevention (CDC), NGS has evolved from being primarily a research tool to becoming a central element in clinical applications over the past five years. This transition highlights NGS's growing importance in understanding the genetic complexities of cancers, which enhances the precision and effectiveness of diagnostic and treatment strategies in clinical practice.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Trade Analysis
• Ecosystem of the Market
• Start-up Analysis
• Patent Analysis
• Customer & Buying Criteria Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Companion Diagnostic Market by Product & Service

• Market Overview
• Assays, Kits, and Reagents
• Instruments & Systems
• Software & Services

Companion Diagnostic Market by Technology

• Market Overview
• Polymerase Chain Reaction
• In Situ Hybridization
• Next-Generation Sequencing
• Immunohistochemistry
• Other Technologies

Companion Diagnostic Market by Indication

• Market Overview
• Cancer
  • Lung Cancer
  • Breast Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Other Cancer
• Neurological Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Other Indications

Companion Diagnostic Market by sample Types

• Market Overview
• Tissue Samples
• Blood Samples
• Other Sample types

Companion Diagnostic Market by End-User

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Reference Laboratories
• Healthcare and Pharmaceutical
• Other End Users

Companion Diagnostic Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• IDEXX Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heska Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDVet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NEOGEN Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AniCell Biotech (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bionote Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Antech Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Animalytix LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Animal Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments